Biomarker hunt: could IFN-Gamma guide melanoma treatment?
NCT ID NCT07436390
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at 132 people with advanced melanoma to see if levels of a protein called interferon-gamma (IFN-γ) in their tumors or blood could predict how well they would respond to first-line immunotherapy drugs like pembrolizumab, nivolumab, or a combination. The goal is to find a reliable biomarker to personalize treatment and avoid giving ineffective therapies. The study also explored whether gut bacteria play a role in treatment outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab, Nivolumab, Ipilimumab/Nivolumab
What this could lead to
If successful, this could help doctors choose the right immunotherapy for each patient, improving response rates and reducing unnecessary side effects.
What could go wrong
This is an observational study, not a treatment trial. The biomarker may not reliably predict response, and results may not change clinical practice immediately.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Oncology Ljubljana
Ljubljana, 1000, Slovenia